1. | Molino D, De Santo NG, Marotta R, Anastasio P, Mosavat M, De Lucia D. Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients. Semin Nephrol 2004; 24 (5): 495 - 501. |
2. | O'shea SI, Lamson JH, Reddan D, Murphy M, Ortel TL. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 2003;38(3): 541-8. |
3. | Schambeck CM, Grossmann R, Zonnur S, Berger M, Teuchert K, Spahn A, Walter U. High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 2004;92(1): 42-6. |
4. | Schmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ. Alterations in hemostatic parameters during hemodialysis with dialysers of different membrane composition and flow design. Platelet activation and factor VIII-related von Willebrand factor during hemodialysis. Am J Med 1987; 83(3):411-8. |
5. | Liam F. Casserly and Laura M. Thrombosis in end-stage renal disease. Seminars in dialy 2003;16(3):245. |
6. | Odegard KC, McGowan FX, Zurakowski D, et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg 2003;125(6): 1260-7. |
7. | Bowen DJ, MacLean RM, Pellard S, Collins PW. High concentrations of coagulation factor VIII and thrombosis: is the factor VIII-binding domain of von Willebrand factor implicated? Br J Haematol 2001;113(3): 655-7. |